Study Name:
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to prior therapy with KRASG12C inhibitors and/or SHP2 inhibitors.
Study Dates:
October 1, 2021 - January 31, 2024
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Revolution Medicines, Inc.
Contact:
Revolution Medicines, Inc.
ContactPhone: (650) 779-2300
ContactEmail: CT-Inquiries@RevMed.com
